The treatment is now just a step away from being the first ever allogeneic stem cell therapy approved in Europe, and will put the Belgium-based biotech company into the vanguard of cell and gene ...

Regenerative medicine company Mesoblast Ltd. is preparing to launch its allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, Ryoncil, (remestemcel-L), in March in the U.S. and has ...

Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies ...

Dr. Bo Wiinberg, chief business development officer at the Novo Nordisk Foundation Cellerator, discusses the current ...

PORTLAND, OR, UNITED STATES, February 25, 2025 /EINPresswire / -- The global cell therapy market is poised for expone ...

Uday R. Popat, MD, discusses a phase 2 trial exploring the use of itacitinib combined with post-transplant cyclophosphamide and tacrolimus to prevent graft-vs-host disease in patients undergoing a ...

Cell therapy is a field rife with innovation ... and returning them to the body, and allogeneic cell therapies, which can be derived from donor cells and sold “off the shelf” to any patient.

Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that it has entered into a Master Services Collaboration Agreement with ...

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage company ...

Eterna Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune diseases, today announced a successful inaugural meeting of its newly ...

DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...

A panel of 10 expert hematologists created recommendations for optimal MRD-guided ALL treatment, which were recently ...